US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% AAPL $333.69 ▲+1.02%
FinancialContent

AngioDynamics, Inc. - Common Stock (NQ:ANGO)

15.11 -0.01 (-0.07%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AngioDynamics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Participate in Upcoming Investor Conferences
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Record Fiscal Year 2026 Fourth Quarter and Full Year Financial Results; Continued Execution Drives Med Tech Growth and Full-Year Profitability
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Participate in the UBS Global Healthcare Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics’ NanoKnife® System Named to TIME’s 2025 Best Inventions List
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism
From AngioDynamics, Inc.
Via Business Wire
News headline image
AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
From AngioDynamics, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >